AGA MetALD Update: Where GLP-1 Drugs Stand

The American Gastroenterological Association published a new Clinical Practice Update on September 22, 2026, covering a liver disease most people on GLP-1 therapy have never heard of: metabolic dysfunction- and alcohol-associated liver disease, or MetALD. The update does not recommend semaglutide as a MetALD treatment. What it says is narrower and more useful: semaglutide, already approved for a closely related liver disease, has not been formally studied in MetALD itself^[1].

What MetALD actually is

Steatotic liver disease, fat buildup in the liver, splits into three categories under the naming system clinicians adopted in 2023. Metabolic dysfunction-associated steatotic liver disease (MASLD) covers people whose fat buildup traces mainly to cardiometabolic risk factors, obesity, type 2 diabetes, high blood pressure, with little to no alcohol involved. Alcohol-associated liver disease (ALD) covers the opposite: heavy drinking with few metabolic risk factors. MetALD sits between the two. The AGA update sets the working alcohol range at roughly 140 to 350 grams a week for women and 210 to 420 grams a week for men, measured over at least three months on top of at least one cardiometabolic risk factor^[1].

The update also asks clinicians to check for alcohol use in every steatotic liver disease patient, not just the ones who volunteer it. Best Practice Advice 2 calls for an alcohol assessment at diagnosis and at least once a year after, using a patient interview, a validated questionnaire, or a blood or urine alcohol biomarker^[1]. The reasoning is direct: alcohol worsens steatosis and fibrosis in a dose-dependent way across nearly every form of chronic liver disease, MetALD included, so a patient's drinking has to be measured before the rest of the picture makes sense.

How the diagnosis actually gets made

For staging, the update favors a tiered approach instead of one single test. It starts with routine blood-based biomarkers and a simple fibrosis score, the Fibrosis-4 Index, to sort out low-risk patients. Anyone who lands in the indeterminate or high-risk group then moves to a second-line test, typically elastography or the serum Enhanced Liver Fibrosis test, to look more closely for advanced fibrosis or cirrhosis^[1]. Active alcohol use can temporarily raise liver stiffness readings on elastography, so a single scan taken shortly after drinking can overstate the fibrosis stage.

Where semaglutide fits, and where it doesn't yet

Best Practice Advice 7 is the line that matters most for anyone already taking a GLP-1 drug. Two medicines are FDA-approved for noncirrhotic MASLD with liver fibrosis: resmetirom and semaglutide. Neither one's safety or efficacy has been formally studied in patients who meet the MetALD definition specifically^[1]. Semaglutide's own FDA label spells out what it is actually approved for: treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, granted under accelerated approval, with continued approval contingent on a confirmatory trial^[2]. MASH and MetALD overlap in some patients but are not the same diagnosis, and the label does not mention MetALD or alcohol use.

The update then adds a caveat rather than a recommendation: preliminary data suggests that GLP-1 and GIP receptor agonists, the drug class that includes both semaglutide and tirzepatide, may reduce alcohol cravings and consumption alongside improving liver-related measurements^[1]. A 2023 Scientific Reports study is one of the pieces of evidence behind that line. Researchers followed 153 adults with obesity who were already drinking alcohol: 54 on a semaglutide product, 50 on tirzepatide, and 47 on neither. Both drug groups reported significantly fewer drinks on average than the group taking neither (p<0.001 for each comparison), and significantly lower odds of binge drinking^[3]. That is observational survey data in people being treated for obesity, not a controlled trial in people with diagnosed MetALD. Best Practice Advice 7 names that gap; it does not close it.

What the update stops short of recommending

The update advises against endobariatric and bariatric surgery for MetALD patients, citing a lack of safety and efficacy data plus concern that continued drinking after surgery could speed up liver disease progression instead of slowing it^[1]. Moderate to severe alcohol use disorder gets its own pharmacotherapy and behavioral care recommendation, separate from any weight-loss or diabetes drug^[1].

A Clinical Practice Update is the AGA's format for guidance on a topic where the evidence base is not yet mature enough for a formally graded guideline. Invited experts write it, the AGA's Clinical Practice Updates Committee reviews it, and the journal peer-reviews it before publication^[4]. The authors say plainly that no systematic review was performed for this one, so the nine Best Practice Advice statements carry expert judgment rather than a formal evidence-quality grade^[1].

What this means if you are on a GLP-1 drug

If you are taking semaglutide or tirzepatide and you also drink, the practical takeaway is not a new prescription. It is a prompt to make sure your alcohol use has actually been asked about and measured, since that is the first step the update wants every steatotic liver disease patient to get. The GLP-1 and alcohol-craving data is real and worth discussing with a clinician who knows your history, but it is preliminary and it is not what either drug is currently approved for. Country-specific prescribing rules for semaglutide are on our regulation page, and none of this replaces a conversation with a doctor who has your labs and your drinking history in front of them.